Constrained Evolution of Human Immunodeficiency Virus Type 1 Protease during Sequential Therapy with Two Distinct Protease Inhibitors

Human immunodeficiency virus type 1 (HIV-1) variants that have developed protease (PR) inhibitor resistance most often display cross-resistance to several molecules within this class of antiretroviral agents. The clinical benefit of the switch to a second PR inhibitor in the presence of such resista...

Szczegółowa specyfikacja

Opis bibliograficzny

Wydane w:	J Virol
Główni autorzy:	Dulioust, Anne, Paulous, Sylvie, Guillemot, Laurent, Delavalle, Anne-Marie, Boué, François, Clavel, François
Format:	Artigo
Język:	Inglês
Wydane:	American Society for Microbiology (ASM) 1999
Hasła przedmiotowe:	Vaccines and Antiviral Agents
Dostęp online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC103902/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/9847401/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/jvi.73.1.850-854.1999
Etykiety:	Dodaj etykietę Nie ma etykietki, Dołącz pierwszą etykiete!